Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
4 minute read

Pfizer Provides Update On Ownership Interest In Haleon; Haleon To Become Publicly Listed Standalone Company In July; Pfizer Will Continue To Hold 32% Ownership In Haleon, Will Exit Ownership Interest In A ‘Disciplined Manner’

By Benzinga Newsdesk
Today, 2:17 PM
Pfizer Provides Update on Ownership Interest in Haleon Haleon to Become a Publicly Listed Standalone Company in July Following a Demerger by GSK Post-Demerger, Pfizer Plans to Exit Ownership Interest in Haleon in a

GSK

Read More
2 minute read

GSK Said ViiV Healthcare Announced Marketing Approval by Japan’s Ministry of Health, Labour and Welfare for Vocabria (cabotegravir) Used in Combination with Rekambys (rilpivirine)

By Charles Gross
Today, 2:17 PM
ViiV Healthcare, the global specialist HIV company majority-owned by GSK with Pfizer and Shionogi as shareholders, today announced it obtained approval for Vocabria (cabotegravir injection and tablets) used in combination with Janssen Pharmaceutical Companies of Johnson & Johnson's Rekambys (rilpivirine long-acting injectable suspension) and Edurant (rilpivirine tablets[*]), the first and only com

GSK

Read More
3 minute read

GSK to Acquire Clinical-stage Biopharmaceutical Company Affinivax for $2.1B Upfront Plus up to $1.2B in Potential Development Milestones

By Charles Gross
Today, 2:17 PM
GSK plc (LSE/NYSE: GSK) today announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones.

GSK